Earnings summaries and quarterly performance for VIVOS.
Research analysts covering VIVOS.
Recent press releases and 8-K filings for RDGL.
Vivos Inc. Updates on RadioGel® Human Therapy Demonstrations in India
RDGL
New Projects/Investments
- Vivos Inc. provided a positive update on its ongoing human therapy demonstrations in India using RadioGel® Precision Radionuclide Therapy™, which were initiated in December 2024.
- To date, no reports of serious adverse events have been received, and preliminary observations include instances of tumor size reduction observed over short intervals with no recurrence, and no reported damage to adjacent organs.
- The company is working towards anticipated DCGI regulatory clearance later this quarter for an expanded phase of therapy in India and plans to update its IDE submission to support the U.S. regulatory pathway.
4 days ago
Vivos Inc. Secures New U.S. Patent and Trademark Approvals
RDGL
Product Launch
New Projects/Investments
- Vivos Inc. (OTCQB: RDGL) announced the issuance of U.S. Patent No. 12,521,452 B2 on January 13, 2026, which protects key advancements in its Precision Radionuclide Therapy™ (PRnT) platform for cancer treatment.
- This patent covers a novel radioactive thermogel suspension, critical for the precise, localized delivery of beta radiation directly into solid tumors using products like RadioGel® and IsoPet®.
- Additionally, the company's PRECISIONGEL™ trademark has been approved for publication in the U.S. and New Zealand, and a new patent application was filed to further protect the hydrogel technology for broader therapeutic agent delivery.
- CEO Dr. Mike Korenko highlighted these milestones as materially enhancing the company's intellectual property, supporting clinical progress, enabling global commercial expansion, and positioning the company for strategic partnerships.
Jan 28, 2026, 1:30 PM
Vivos Inc. Reports Significant Growth and Expansion in IsoPet Division
RDGL
Revenue Acceleration/Inflection
New Projects/Investments
- Vivos Inc.'s IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, indicating accelerating veterinary adoption and growing awareness, with over 100 IsoPet treatments safely performed.
- The company expanded its network by certifying two new clinics, Sun City Veterinary Surgery Center and the University of Florida Small Animal Hospital, bringing the total to 17 certified clinics by the end of 2025.
- Starting in Q1 2026, the IsoPet division will implement profitability-focused initiatives and anticipates revenue generation from case study therapies in 2026 after their completion.
Dec 22, 2025, 5:56 PM
Vivos Inc. Summarizes Progress in its Animal Therapy Division
RDGL
Revenue Acceleration/Inflection
New Projects/Investments
- Vivos Inc.'s IsoPet division reported an 800% year-over-year increase in administered therapies from 2024 to 2025, with pet patients treated growing +1,200% year-over-year in 2025.
- The company expanded its network by certifying two new clinics, Sun City Veterinary Surgery Center and the University of Florida Small Animal Hospital, bringing the total clinic count to 17 by the end of 2025.
- The IsoPet division will implement profitability-focused initiatives starting in Q1 2026, and therapies currently subsidized for case studies, which are 80% completed, are expected to begin generating revenue after completing studies in 2026.
Dec 22, 2025, 1:30 PM
Vivos Inc. Provides Update on Regulatory Progress, International Expansion, and Product Development
RDGL
New Projects/Investments
Product Launch
Guidance Update
- Vivos Inc. is actively pursuing FDA Investigational Device Exemption (IDE) approval for RadioGel, having engaged a regulatory expert and filed a Pre-Submission on sterilization, with a second Pre-Submission in preparation for a near-term full IDE application.
- The company established Vivos Scientific India LLP (VISL) in September 2025 to accelerate regulatory approvals, establish manufacturing, and access India's human oncology and veterinary therapy markets for RadioGel and Isopet.
- The IsoPet division experienced an 800% year-over-year increase in administered therapies from 2024 to 2025, with over 100 treatments safely performed across various animals.
- Vivos plans to transition from fully outsourced manufacturing by H1 2026, with new domestic and international production centers anticipated to be operational in Q2 2026.
- PrecisionGel, a hydrogel polymer, is now commercially available, and a laboratory chilling prototype, Duncan Chiller, is planned for commercialization in 2026.
Nov 6, 2025, 1:30 PM
Vivos Inc. Appoints Dr. John J. Smith as Lead Regulatory Advisor for RadioGel® IDE Submission
RDGL
Hiring
New Projects/Investments
- Vivos Inc. (OTCQB: RDGL) has appointed Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as lead regulatory advisors.
- Their primary role is to support the FDA Investigational Device Exemption (IDE) submission for RadioGel®.
- This appointment is a critical step for Vivos Inc. to initiate U.S. clinical trials for RadioGel® at the Mayo Clinic.
Oct 27, 2025, 12:30 PM
Vivos Inc. Board Authorizes Indian Subsidiary for Manufacturing and Trials
RDGL
New Projects/Investments
- The Vivos Inc. Board has authorized the formation of Vivos Scientific India LLP, a wholly-owned corporate subsidiary in India, with formal approvals from the Indian government currently being completed.
- This initiative demonstrates a long-term commitment to India and aims to establish the company's first international manufacturing center for RadioGel and IsoPet.
- The subsidiary will also support the expansion of developmental animal testing and the commercial treatment of humans and animals in India.
- Vivos Inc. is actively pursuing DCGI approval for additional expanded human trials in India, following the initiation of first-in-human trials in December 2024.
- Future human trials in India will include immediate post-treatment PET full-body scans to validate RadioGel's safety profile, based on feedback from the FDA for the IDE application process.
Sep 29, 2025, 5:46 PM
Vivos Inc. Board Authorizes Establishment of Indian Subsidiary
RDGL
New Projects/Investments
- Vivos Inc.'s Board has authorized the formation of a wholly owned corporate subsidiary in India, to be named Vivos Scientific India LLP.
- This move is part of the company's long-term commitment to India and aims to establish its first international manufacturing center for RadioGel and IsoPet, expand developmental animal testing, and facilitate commercial treatment for humans and animals in the region.
- Vivos initiated first-in-human trials in India in December 2024 and is actively pursuing Drug Controller General of India (DCGI) approval for additional expanded human trials.
- These India trials are intended to support the company's Investigational Device Exemption (IDE) process with the FDA, with future trials including immediate post-treatment PET full-body scans to validate RadioGel's safety profile.
Sep 29, 2025, 12:30 PM
Vivos Inc. Validates New Hydrogel Sterilization Process
RDGL
New Projects/Investments
Revenue Acceleration/Inflection
- Vivos Inc. has successfully validated a new electron beam (E-Beam) sterilization process for its hydrogel, following nearly a year of testing and validation under ISO 11137 by an international medical device accredited organization.
- This E-Beam process achieves a sterility assurance level of 10-6, which is the most rigorous level, minimizing infection risk for critical medical devices.
- The process is more cost-effective, improves production yield, and significantly enhances scalability for commercial growth.
- It benefits both human (Radiogel®) and animal (IsoPet®) therapies, driving greater manufacturing efficiency and enabling more consistent supply and cost-effective production.
Sep 3, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more